Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 12/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117051 | 0.92 | ALDH1A1 (0.49) | TACR1ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL5121358 | 0.92 | TRPM8 (0.50) | TRPM8USP2CYP1A2CYP2C9EPHX2 | |
| SCHEMBL5124367 | 0.91 | EPHX2 (0.47) | TACR1TRPM8USP2CYP1A2CYP2C9 | |
| SCHEMBL5115812 | 0.91 | ALDH1A1 (0.54) | TACR1ALDH1A1TRPM8RAB9ACYP1A2 | |
| SCHEMBL5124412 | 0.90 | USP2 (0.55) | ALDH1A1TRPM8USP2CYP1A2CYP2C9 | |
| SCHEMBL5124886 | 0.89 | EPHX2 (0.52) | ALDH1A1TRPM8EPHX2 | |
| SCHEMBL5117042 | 0.89 | TRPM8 (0.51) | TRPM8USP2CYP1A2CYP2C9EPHX2 | |
| SCHEMBL5124232 | 0.89 | TRPM8 (0.52) | TRPM8PAX8EPHX2 | |
| SCHEMBL5120071 | 0.89 | ALDH1A1 (0.54) | ALDH1A1RAB9A | |
| SCHEMBL5130518 | 0.89 | TRPM8 (0.56) | TRPM8EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | claimed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | TACR1 337/4885ALDH1A1 511/4885TRPM8 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.